Spironolactone

Generic Name
Spironolactone
Brand Names
Aldactazide, Aldactone, Carospir, Qaialdo
Drug Type
Small Molecule
Chemical Formula
C24H32O4S
CAS Number
52-01-7
Unique Ingredient Identifier
27O7W4T232
Background

Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several ...

Indication

Spironolactone is indicated for the treatment of the following conditions:

As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.

Associated Conditions
Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
Associated Therapies
Perioperative drug treatment, Maintenance therapy
Clinical Trials
Related News

Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone

First Posted Date
2024-10-15
Last Posted Date
2024-10-15
Lead Sponsor
Ahmad Abdullah Salawi
Target Recruit Count
494
Registration Number
NCT06641284
Locations
🇸🇦

King Fahd Central Hospital, Al 'Usaylah, Saudi Arabia

Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment

First Posted Date
2024-05-14
Last Posted Date
2024-05-16
Lead Sponsor
Ospedale San Raffaele
Target Recruit Count
38
Registration Number
NCT06413082
Locations
🇮🇹

San Raffaele Hospital, Milan, Lombardia, Italy

🇮🇹

IRCCS Ospedale San Raffaele, Milan, Italy

SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation

Phase 3
Not yet recruiting
Conditions
Atrial Fibrillation Recurrent
Interventions
Drug: Spironolactone
First Posted Date
2024-01-12
Last Posted Date
2024-01-12
Lead Sponsor
University Hospital, Caen
Target Recruit Count
580
Registration Number
NCT06204640

Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

Phase 4
Not yet recruiting
Conditions
Primary Aldosteronism
Interventions
Drug: Spironolactone
Drug: Finerenone
First Posted Date
2023-12-11
Last Posted Date
2023-12-11
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
150
Registration Number
NCT06164379
Locations
🇨🇳

Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Determination of Drug Levels for Pharmacotherapy of Heart Failure

First Posted Date
2023-09-13
Last Posted Date
2024-01-18
Lead Sponsor
University Hospital Ostrava
Target Recruit Count
100
Registration Number
NCT06035978
Locations
🇨🇿

University Hospital Ostrava, Ostrava, Czech Republic, Czechia

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1

Not Applicable
Recruiting
Conditions
Alcohol Use Disorder
Hiv
Interventions
Drug: Spironolactone
First Posted Date
2023-08-22
Last Posted Date
2024-06-10
Lead Sponsor
Yale University
Target Recruit Count
30
Registration Number
NCT06004830
Locations
🇺🇸

Atlanta VA Medical Center, Decatur, Georgia, United States

Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)

First Posted Date
2023-08-22
Last Posted Date
2023-08-22
Lead Sponsor
University of Sao Paulo
Target Recruit Count
264
Registration Number
NCT06005259
Locations
🇧🇷

Instituto do Coração, São Paulo, Brazil

Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism

Phase 4
Not yet recruiting
Conditions
Primary Aldosteronism
Hypertension
Interventions
Drug: Finerenone
Drug: Spironolactone
First Posted Date
2023-04-18
Last Posted Date
2023-04-18
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Target Recruit Count
96
Registration Number
NCT05814770

Spironolactone in Alcohol Use Disorder (SAUD)

Phase 1
Recruiting
Conditions
Alcohol Use Disorder
Interventions
Other: Placebo
Drug: Spironolactone
First Posted Date
2023-04-11
Last Posted Date
2024-12-13
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
20
Registration Number
NCT05807139
Locations
🇺🇸

National Institute on Drug Abuse, Baltimore, Maryland, United States

Quadruple Immunotherapy for Neuroblastoma

First Posted Date
2023-03-06
Last Posted Date
2024-10-03
Lead Sponsor
Hong Kong Children's Hospital
Target Recruit Count
29
Registration Number
NCT05754684
Locations
🇭🇰

Hong Kong Children's Hospital, Hong Kong, Hong Kong

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy